1 / 26

Monitoring Patients on Anti-TB Medications

Monitoring Patients on Anti-TB Medications. Reynard J. McDonald, MD Medical Director, Lattimore Practice Northeast National Tuberculosis Center at NJMS. Adverse Side Effect.

paul
Télécharger la présentation

Monitoring Patients on Anti-TB Medications

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Monitoring Patients on Anti-TB Medications Reynard J. McDonald, MD Medical Director, Lattimore Practice Northeast National Tuberculosis Center at NJMS

  2. Adverse Side Effect • Any unexplained, unintended, undesired, or excessive response to a medication, used at recommended doses that may require: • Discontinuation of the medication (therapeutic or diagnostic) • Modifying the dose (except for minor dosage adjustments) • Prolonging treatment

  3. Adverse Side Effects Cont’d • Adverse drug reactions may lead to complications: • Prevents optimal drug use in some patients • Necessitates supportive care • Significantly complicates treatment • Decreases patient’s quality of life • Results in temporary or permanent harm, disability, or death

  4. Scope of Problem • The fourth leading cause of death in the US is adverse drug reactions (ADRs) • Only heart disease, cancer, and stroke kill more Americans than ADRs • The number of deaths from ADRs is three times the number of deaths from people killed by automobile accidents

  5. Risk Factors for Developing an ADR • Multiple drug therapy • Over the counter medications • Alcohol • Drugs of abuse • Number of drugs • Age • Very young • Very old • Pregnancy • Risk to fetal development (first trimester, phenytoin) • Co-morbidity/chronic diseases – can alter a drug’s absorption, distribution, metabolism or elimination • Hereditary factors – slow acetylators

  6. Monitoring for Adverse Reactions • Health care workers should be educated about: • Name(s) of medication • Common side effects • More serious reactions • What to do if symptoms occur • What to do if patients have other behaviors that may interfere with their treatment • What to do if a dose is missed • How to report an ADR

  7. Monitoring for Adverse Reactions • During treatment, patients should be questioned and evaluated for: • Signs and symptoms of possible side effects • Use open-ended questions to obtain more information • While in the field, health care workers should: • Make observations about the patient and the surrounding environment • Take appropriate action to address and correct the adverse reaction

  8. How Do I Report an ADR? • Depends on each individual TB program • e.g., telephone, email, fax, or mail • Follow the TB Program’s standard procedure for reporting ADRs • Ensure complete documentation of all pertinent information

  9. TB Medications That Can Cause an ADR • First-Line Anti-TB Medications • Isoniazid (INH) • Rifampin (RIF) • Rifabutin (RFB) • Rifapentine (RPT) • Ethambutol (EMB) • Pyrazinamide (PZA) • Second-Line Anti-TB Medications

  10. Isoniazid (INH) • Adverse effects: • Hepatic enzyme elevation • Hepatitis • Peripheral neuropathy • CNS effects • SLE-like symptoms • Hypersensitivity reaction • Monoamine (Histamine/tyramine poisoning) • Diarrhea

  11. INH Drug Interactions & Monitoring • Drug Interaction • Phenytoin • Monitoring • Routine monitoring is not necessary • For patients with pre-existing liver disease or who develop abnormal liver function test should be measured monthly and when symptoms occur • Prevention • Vitamin B6 may prevent peripheral neuropathy and CNS effects

  12. Rifampin (RIF) • Adverse effects: • Cutaneous reactions • Gastrointestinal reactions • Flu-like syndrome • Hepatotoxicity • Severe immunologic reactions • Orange discoloration of bodily fluids • Patients should be informed in advance of urine and contact lens discoloration

  13. RIF Drug Interactions • Drug Interactions • Antiinfectives • Hormone therapy • Narcotics • Anticoagulants • Immunosuppressive agents • Anticonvulsants • Cardiovascular agents • Bronchodilators • Sulfonylurea hypoglycemics • Hypolipidemics • Psychotropic drugs

  14. RIF Monitoring • Monitoring • No routine monitoring required • When given with drugs that interact, may necessitate regular measurements of the serum concentrations of the drugs in question

  15. Rifabutin (RFB) • Adverse effects: • Hematologic toxicity • Uveitis • GI symptoms • Polyarthralgia • Hepatitis • Rash • Orange discoloration of bodily fluids • Drug interactions and monitoring – see RIF

  16. Rifapentine (RPT) • Adverse effects: • Similar to those associated with RIF • May increase metabolism of co-administered drugs that are metabolized by hepatic enzymes • Drug Interactions: • Are likely to be similar to those of RIF • Monitoring: • Similar to that for RIF

  17. Ethambutol (EMB) • Adverse effect: • Optic neuritis (impaired perception of the red and green colors) • Cutaneous reactions • Monitoring • Baseline and monthly tests of visual acuity and color vision • Educate patient about self monitoring their vision and reporting any visual changes to their physician immediately

  18. Pyrazinamide (PZA) • Adverse effects: • Hepatotoxicity • GI symptoms • Non-gouty polyarthralgia • Hyperuricemia • Acute gouty arthritis • Rash • Monitoring • Serum uric acid measurements are not routinely recommended • Liver function tests should be performed when the drug is used in patients with underlying liver disease

  19. Second-Line Anti-TB Medications • Cycloserine • Ethionamide • Levofloxacin • Moxifloxacin • Gatifloxacin • p-Aminosalicylic acid (PAS) • Streptomycin • Amikacin/Kanamycin • Capreomycin

  20. Second-Line Anti-TB Medications • Cycloserine • Psychosis, seizures • Ethionamide and PAS • GI upset • Fluoroquinolones • Tendon rupture • Aminoglycosides • Deafness • Renal failure

  21. Patient Education • Health care workers must clearly explain to patients the following: • When the medication should be taken • How much • How often • All patients should be educated about: • TB • Medication dosages • Possible side effects • Importance of taking the medication

  22. Additional Challenges • Close supervision is necessary for patients who abuse alcohol and other drugs to: • Ensure adherence • Monitor for medication side effects and adverse reactions • Directly observed therapy (DOT) and case management can produce the best results

  23. Questions To Ask • How do you feel? • Do you have any of the following: • Abdominal pain • Fatigue • Unusual breathing • Rash • Joint pains/swellings • Other unusual symptoms

  24. Questions Cont’d • Are you taking any medications other than anti-TB medications? • Prescription medications, herbal remedies or vitamins • How is your appetite? • How do you feel after you take the medications? • Have you had any weight gain or loss? • What color is your urine (should be orange for patients on rifampin)? • Do you have any fever?

  25. Patient Observation • Does the patient have signs and symptoms of hepatitis including any of the following: • Yellow eyes • Yellow skin • Nausea or vomiting • Does the patient have any rash? • Is the patient gaining weight? • Are you having any problems taking the anti-TB medications?

  26. Importance of Monitoring • Close monitoring of patients throughout treatment can: • Prevent serious complications • Promote continuity of care • Improve patient-health care provider relationship • Encourage adherence • Ensure successful completion of treatment

More Related